达格列净对2型糖尿病患者血压影响的系统评价(3)
综上所述，达格列净能够明显降低2型糖尿病患者的血压，同时由血容量不足引起的低血压事件风险低，这些将有可能给2型糖尿病合并高血压患者提供一种新的药物治疗手段。
参考文献
[1]张祥溢，孙先英.糖尿病并高血压患者心、肾、脑终点事件观察[J].实用糖尿病杂志，2007，3(3)：21-22.
[2]Meng W，Ellsworth B A，Nirschl A A，et al.Discovery of dapagliflozin：a potent，selective renal sodium-dependent glucose cotransporter 2(SGLT2) inhibitor for the treatment of type 2 diabetes[J].J Med Chem，2008，51(5)：1145-1149.
, 百拇医药
[3] Higgins J P T，Green S.Cochrane handbook for systematic reviews of interventions [M].The Cochrane Collaboration，2011：1-6.
[4] Wilding J P，Norwood P，T’joen C，et al.A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers：applicability of a novel insulin-independent treatment[J].Diabetes Care，2009，32(9)：1656-1662.
[5] List J F，Woo V，Morales E，et al.Sodium-glucose cotransort inhibition with dapagliflozin in type 2 diabetes[J].Diabetes Care，2009，32(4)：650-657.
, 百拇医药
[6] Ferrannini E，Ramos S J，Salsali A，et al.Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise：a randomized，double-blind，placebo-controlled，phase 3 trial[J].Diabetes Care，2010，33(10)：2217-2224.
[7] Strojek K，Yoon K H，Hruba V，et al.Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemiccontrol with glimepiride：a randomized，24-week，double-blind，placebo-controlled trial[J].Diabetes Obes Metab，2011，13(10)：928-938.
, http://www.100md.com
[8] Henry R R，Murray A V，Marmolejo M H，et al.Dapagliflozin，metformin XR，or both：initial pharmacotherapy for type 2 diabetes，a randomised controlled trial[J].Int J Clin Pract，2012，66(5)：446-456.
[9] Wilding J P，Woo V，Soler N G，et al.Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin：a randomized trial[J].Ann Intern Med，2012，156(6)：405-415.
[10] Rosenstock J，Vico M，Wei L，et al. Effects of dapagliflozin， an SGLT2 inhibitor，on HbA(1c)，body weight，and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy[J].Diabetes Care，2012，35(7)：1473-1478.
, 百拇医药
[11] Bailey C J，Iqbal N，T’joen C，et al.Dapagliflozin monotherapy in drug-naive patients with diabetes：a randomized-controlled trial of low-dose range[J].Diabetes Obes Metab，2012，14(10)：951-959.
[12] Bailey C J，Gross J L，Hennicken D，et al.Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin：a randomized，double-blind，placebo-controlled 102-week trial[J].BMC Med，2013，1(11)：43., 百拇医药(陈丽等)
参考文献
[1]张祥溢，孙先英.糖尿病并高血压患者心、肾、脑终点事件观察[J].实用糖尿病杂志，2007，3(3)：21-22.
[2]Meng W，Ellsworth B A，Nirschl A A，et al.Discovery of dapagliflozin：a potent，selective renal sodium-dependent glucose cotransporter 2(SGLT2) inhibitor for the treatment of type 2 diabetes[J].J Med Chem，2008，51(5)：1145-1149.
, 百拇医药
[3] Higgins J P T，Green S.Cochrane handbook for systematic reviews of interventions [M].The Cochrane Collaboration，2011：1-6.
[4] Wilding J P，Norwood P，T’joen C，et al.A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers：applicability of a novel insulin-independent treatment[J].Diabetes Care，2009，32(9)：1656-1662.
[5] List J F，Woo V，Morales E，et al.Sodium-glucose cotransort inhibition with dapagliflozin in type 2 diabetes[J].Diabetes Care，2009，32(4)：650-657.
, 百拇医药
[6] Ferrannini E，Ramos S J，Salsali A，et al.Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise：a randomized，double-blind，placebo-controlled，phase 3 trial[J].Diabetes Care，2010，33(10)：2217-2224.
[7] Strojek K，Yoon K H，Hruba V，et al.Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemiccontrol with glimepiride：a randomized，24-week，double-blind，placebo-controlled trial[J].Diabetes Obes Metab，2011，13(10)：928-938.
, http://www.100md.com
[8] Henry R R，Murray A V，Marmolejo M H，et al.Dapagliflozin，metformin XR，or both：initial pharmacotherapy for type 2 diabetes，a randomised controlled trial[J].Int J Clin Pract，2012，66(5)：446-456.
[9] Wilding J P，Woo V，Soler N G，et al.Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin：a randomized trial[J].Ann Intern Med，2012，156(6)：405-415.
[10] Rosenstock J，Vico M，Wei L，et al. Effects of dapagliflozin， an SGLT2 inhibitor，on HbA(1c)，body weight，and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy[J].Diabetes Care，2012，35(7)：1473-1478.
, 百拇医药
[11] Bailey C J，Iqbal N，T’joen C，et al.Dapagliflozin monotherapy in drug-naive patients with diabetes：a randomized-controlled trial of low-dose range[J].Diabetes Obes Metab，2012，14(10)：951-959.
[12] Bailey C J，Gross J L，Hennicken D，et al.Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin：a randomized，double-blind，placebo-controlled 102-week trial[J].BMC Med，2013，1(11)：43., 百拇医药(陈丽等)